TNXP
Tonix Pharmaceuticals Holding Corp.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Sell
-44/100
Last price
7.81
▼ 0.26 (3.22%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
7.81
Prev close
8.07
Day high
8.31
Day low
7.69
Volume
2.54M
Market cap
$131.98M
P/E (TTM)
—
52W range
7.69 – 24.49
Day trading desk
Gap from prior close
-3.22%
Prior close 8.07
VWAP
—
—
Relative volume
0.00×
Quiet session
Session range
—
7.81 – 7.81
Position in range
—
—
ATR (14D)
0.62
7.96% of price
Prior day high
8.82
PDH
Prior day low
8.00
PDL
Bid / ask spread
—
Quote not published
Session volume
—
Avg 501.70K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-20.21%
-22.2%
1M
-41.40%
-42.6%
3M
-39.75%
-44.3%
6M
-41.09%
-59.3%
YTD
-50.70%
-65.0%
1Y
-67.92%
-84.3%
3Y
-99.56%
-181.8%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
10 more panels on TNXP open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
27.44K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 12, 26 | TAYLOR CAROLYN E. Director |
BUY | 1.42K | $14.93K | Direct |
| Jun 9, 26 | LEDERMAN SETH Chief Executive Officer |
BUY | 5.00K | $58.95K | Direct |
| Jun 8, 26 | STILLWELL RICHARD NEWCOMB Director |
BUY | 5.00K | $58.25K | Direct |
| Mar 31, 26 | LEDERMAN SETH Chief Executive Officer |
BUY | 5.00K | $63.10K | Indirect |
| Mar 18, 26 | LEDERMAN SETH Chief Executive Officer |
BUY | 15.00K | $223.35K | Indirect |
| Dec 31, 25 | SAENGER BRADLEY Chief Financial Officer |
STOCK | 701 | $9.41K | Direct |
| Aug 21, 25 | TAYLOR CAROLYN E. Director |
BUY | 418 | $15.06K | Direct |
| Aug 20, 25 | TRECO JAMES Director |
BUY | 250 | $9.00K | Direct |
| May 15, 25 | LEDERMAN SETH Chief Executive Officer |
BUY | 4.00K | $86.20K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
LEDERMAN SETH |
Chief Executive Officer | 29.01K | Purchase |
SAENGER BRADLEY |
Chief Financial Officer | 701 | Stock Award(Grant) |
STILLWELL RICHARD NEWCOMB |
Director | 5.00K | Purchase |
TAYLOR CAROLYN E. |
Director | 1.83K | Purchase |
TRECO JAMES |
Director | 250 | Purchase |
Fundamentals
Market cap$131.98M
Enterprise value$-42.98M
Revenue (TTM)$29.10M
Gross profit$24.40M
EBITDA$-163.30M
Net income$-159.67M
EPS (TTM)$-13.06
Free cash flow$-95.76M
Total cash$176.23M
Total debt$1.27M
Book value / share$13.24
Shares outstanding17.15M
Float14.12M
Short % of float16.57%
Dividend yield0.00%
Beta (5Y)1.79
Valuation & profitability ratios
Trailing P/E—
Forward P/E-0.98
PEG ratio—
Price / sales—
Price / book0.58
EV / revenue-1.48
EV / EBITDA0.26
Gross margin83.83%
Operating margin-314.05%
Profit margin0.00%
Return on equity-81.82%
Return on assets-46.84%
Debt / equity0.57
Current ratio6.61
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $13.11M | $10.09M | $7.77M | $0 | — | +29.8% |
| Operating revenue | $13.11M | $10.09M | $7.77M | $0 | — | +29.8% |
| Cost of revenue | $6.64M | $7.76M | $4.74M | $0 | — | -14.5% |
| Gross profit | $6.47M | $2.33M | $3.03M | $0 | — | +177.7% |
| Research & development | $44.49M | $39.97M | $86.66M | $81.88M | — | +11.3% |
| Selling, general & admin | $87.68M | $40.10M | $34.75M | $30.21M | — | +118.7% |
| Total operating expense | $129.16M | $77.48M | $121.41M | $112.09M | — | +66.7% |
| Operating income | -$122.69M | -$75.15M | -$118.38M | -$112.09M | — | -63.3% |
| Net interest income | $4.06M | -$1.21M | — | $1.87M | $25.00K | +434.7% |
| Pre-tax income | -$124.02M | -$130.04M | -$116.66M | -$110.22M | — | +4.6% |
| Net income | -$124.02M | -$130.04M | -$116.66M | -$110.22M | — | +4.6% |
| Net income to common | -$124.02M | -$130.04M | -$116.66M | -$116.88M | — | +4.6% |
| Basic EPS | -14.57 | -176.60 | -14,720.25 | -65,400.00 | — | +91.7% |
| Diluted EPS | -14.57 | -176.60 | -14,720.25 | -65,400.00 | — | +91.7% |
| EBIT | -$123.93M | -$128.80M | -$118.38M | -$112.09M | — | +3.8% |
| EBITDA | -$122.01M | -$125.38M | -$114.09M | -$110.84M | — | +2.7% |
| Basic shares | 8.51M | 736.34K | 7.92K | 1.79K | — | +1,055.9% |
| Diluted shares | 8.51M | 736.34K | 7.92K | 1.79K | — | +1,055.9% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $207.64M | $98.78M | $24.95M | $120.23M | +110.2% |
| Cash & short-term investments | $207.64M | $98.78M | $24.95M | $120.23M | +110.2% |
| Accounts receivable | $6.27M | $3.68M | $0 | — | +70.3% |
| Inventory | $7.01M | $8.41M | $14.15M | $0 | -16.6% |
| Total current assets | $228.88M | $119.00M | $47.77M | $130.78M | +92.3% |
| Property, plant & equipment | $46.00M | $42.82M | $94.85M | $94.53M | +7.4% |
| Goodwill & intangibles | $120.00K | $120.00K | $10.71M | $120.00K | 0.0% |
| Total assets | $277.17M | $162.89M | $154.46M | $225.69M | +70.2% |
| Total current liabilities | $30.84M | $18.31M | $18.88M | $18.18M | +68.4% |
| Long-term debt | — | $4.67M | $6.56M | — | — |
| Total debt | $1.31M | $8.12M | $9.81M | $760.00K | -83.9% |
| Total liabilities | $32.02M | $23.33M | $48.93M | $18.51M | +37.2% |
| Retained earnings | -$854.72M | -$730.69M | -$600.66M | -$470.04M | -17.0% |
| Shareholder equity | $245.15M | $139.56M | $105.53M | $207.18M | +75.7% |
| Working capital | $198.04M | $100.69M | $28.88M | $112.60M | +96.7% |
| Net tangible assets | $245.03M | $139.44M | $94.82M | $207.06M | +75.7% |
| Shares issued | 12.79M | 4.39M | 18.32K | 3.82K | +191.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$124.02M | -$130.04M | -$116.66M | -$110.22M | +4.6% |
| Depreciation & amortisation | $1.93M | $3.42M | $4.29M | $1.25M | -43.7% |
| Stock-based compensation | $6.02M | $4.78M | $9.28M | $10.91M | +25.9% |
| Change in working capital | $8.54M | $5.78M | -$35.00K | -$2.00K | +48.0% |
| Operating cash flow | -$99.84M | -$60.92M | -$102.00M | -$98.05M | -63.9% |
| Capital expenditure | -$3.37M | -$120.00K | -$7.89M | -$48.15M | -2,707.5% |
| Investing cash flow | -$4.53M | -$120.00K | -$29.07M | -$48.15M | -3,673.3% |
| Share buybacks | -$13.76M | $0 | -$13.96M | -$47.25M | — |
| Financing cash flow | $214.53M | $134.87M | $36.52M | $87.84M | +59.1% |
| Free cash flow | -$103.21M | -$61.05M | -$109.90M | -$146.20M | -69.1% |
| End cash position | $209.81M | $99.68M | $25.85M | $120.47M | +110.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $13.54M | $6.88M | $5.39M | $3.29M | $2.00M | +96.9% |
| Operating revenue | $13.54M | $6.88M | $5.39M | $3.29M | $2.00M | +96.9% |
| Cost of revenue | $703.00K | $1.58M | $1.06M | $1.37M | $3.27M | -55.4% |
| Gross profit | $12.84M | $5.30M | $4.33M | $1.92M | -$1.27M | +142.3% |
| Research & development | $19.42M | $18.21M | $16.94M | $9.29M | $10.82M | +6.6% |
| Selling, general & admin | $35.96M | $28.62M | $35.68M | $25.70M | $16.20M | +25.6% |
| Total operating expense | $54.78M | $46.84M | $52.55M | $34.01M | $25.99M | +17.0% |
| Operating income | -$41.94M | -$41.54M | -$48.22M | -$32.09M | -$27.26M | -1.0% |
| Net interest income | $1.43M | $1.35M | $1.34M | $1.23M | $943.00K | +6.4% |
| Pre-tax income | -$40.55M | -$40.19M | -$46.91M | -$32.01M | -$28.27M | -0.9% |
| Net income | -$40.55M | -$40.19M | -$46.91M | -$32.01M | -$28.27M | -0.9% |
| Net income to common | -$40.55M | -$40.19M | -$46.91M | -$32.01M | -$28.27M | -0.9% |
| Basic EPS | -2.44 | -2.93 | -3.98 | -3.59 | -3.86 | +16.7% |
| Diluted EPS | -2.44 | -2.93 | -3.98 | -3.59 | -3.86 | +16.7% |
| EBIT | -$41.94M | -$41.54M | -$46.91M | -$32.01M | -$27.26M | -1.0% |
| EBITDA | -$41.32M | -$40.98M | -$46.42M | -$31.55M | -$26.78M | -0.8% |
| Basic shares | 16.64M | 13.71M | 11.80M | 8.92M | 7.33M | +21.4% |
| Diluted shares | 16.64M | 13.71M | 11.80M | 8.92M | 7.33M | +21.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $176.23M | $185.47M | $207.64M | $190.06M | $125.33M | -5.0% |
| Cash & short-term investments | $176.23M | $185.47M | $207.64M | $190.06M | $125.33M | -5.0% |
| Accounts receivable | $11.80M | $8.82M | $6.27M | $3.48M | $2.32M | +33.8% |
| Inventory | $5.68M | $4.64M | $7.01M | $5.73M | $5.99M | +22.2% |
| Total current assets | $203.43M | $207.17M | $228.88M | $208.07M | $143.53M | -1.8% |
| Property, plant & equipment | $46.11M | $46.34M | $46.00M | $42.95M | $42.77M | -0.5% |
| Goodwill & intangibles | $120.00K | $120.00K | $120.00K | $120.00K | $120.00K | 0.0% |
| Total assets | $254.09M | $257.91M | $277.17M | $252.44M | $187.36M | -1.5% |
| Total current liabilities | $30.79M | $29.65M | $30.84M | $21.03M | $19.06M | +3.8% |
| Total debt | $1.27M | $1.29M | $1.31M | $425.00K | $492.00K | -1.4% |
| Total liabilities | $31.81M | $30.77M | $32.02M | $21.30M | $19.36M | +3.4% |
| Retained earnings | -$935.46M | -$894.91M | -$854.72M | -$807.80M | -$775.79M | -4.5% |
| Shareholder equity | $222.28M | $227.14M | $245.15M | $231.14M | $168.00M | -2.1% |
| Working capital | $172.65M | $177.52M | $198.04M | $187.04M | $124.47M | -2.7% |
| Net tangible assets | $222.16M | $227.02M | $245.03M | $231.02M | $167.88M | -2.1% |
| Shares issued | 16.79M | 14.21M | 12.79M | 10.17M | 7.36M | +18.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$40.55M | -$40.19M | -$46.91M | -$32.01M | -$28.27M | — | -0.9% |
| Depreciation & amortisation | $619.00K | $555.00K | $488.00K | $461.00K | $483.00K | — | +11.5% |
| Stock-based compensation | $2.26M | $1.97M | $1.79M | $1.92M | $1.42M | — | +14.5% |
| Change in working capital | -$4.57M | -$4.65M | $3.79M | $616.00K | $7.42M | — | +1.8% |
| Operating cash flow | -$42.24M | -$42.32M | -$39.65M | -$28.78M | -$14.83M | — | +0.2% |
| Capital expenditure | -$587.00K | -$1.69M | -$1.87M | — | -$2.54M | -$6.00K | +65.3% |
| Investing cash flow | -$587.00K | -$1.69M | -$1.02M | -$962.00K | -$2.54M | — | +65.3% |
| Share buybacks | $0 | $0 | -$7.81M | $0 | -$2.90M | — | — |
| Financing cash flow | $33.51M | $20.20M | $59.14M | $94.86M | $10.99M | — | +65.8% |
| Free cash flow | -$42.83M | -$44.01M | -$41.52M | -$27.73M | -$17.37M | — | +2.7% |
| End cash position | $176.62M | $186.01M | $209.81M | $191.35M | $126.24M | — | -5.0% |
Options analytics
Put / call volume
3.74
Put-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
5.00
-35.0% from spot
ATM implied vol
50.0%
Nearest strike to spot
Skew (10% OTM)
-43.7%
Calls bid over puts
Call volume
23
Contracts, this expiry
Put volume
86
Contracts, this expiry
Heaviest call OI
10.00
0 contracts
Heaviest put OI
5.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -2.62 | -2.47 | +5.6% |
| Mar 2026 | -2.54 | -2.93 | -15.4% |
| Dec 2025 | -2.94 | -3.98 | -35.4% |
| Sep 2025 | -2.75 | -3.70 | -34.4% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -2.33 | 2 | $15.87M | +382.4% |
| Next quarter | -2.35 | 2 | $18.83M | +249.3% |
| Current year | -9.95 | 2 | $55.00M | +319.6% |
| Next year | -7.88 | 2 | $110.89M | +101.6% |
Analyst targets & ownership
Mean target$44.50
High target$65.00
Low target$22.00
Implied upside469.78%
Analyst count4
ConsensusSTRONG BUY
Strong buy / Buy0 / 3
Hold0
Sell / Strong sell0 / 0
Held by insiders0.16%
Held by institutions55.98%
Institutions holding146
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
9.30
-16.02% from price
SMA 20
10.43
-26.21% from price
SMA 50
11.56
-33.41% from price
SMA 100
11.87
-34.21% from price
SMA 200
13.39
-42.50% from price
EMA 12
9.45
-17.38% from price
EMA 26
10.49
-25.57% from price
EMA 50
11.20
-30.27% from price
RSI (14)
16.3
Oversold
MACD (12,26,9)
-1.04
Hist -0.27
ATR (14)
0.62
8.07% of price
Realised vol 30D
53.1%
Annualised
Bollinger upper
13.13
20, 2σ
Bollinger lower
7.73
20, 2σ
50 / 200 cross
Death
11.56 vs 13.39
Trend bias
Below 200
-42.50%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.86
More volatile than market
Correlation to SPY
0.34
Loosely linked
Realised vol 30D
53.1%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-68.2%
Peak to trough
Max drawdown 5Y
-100.0%
Peak to trough
ATR 14
0.62
8.07% of price
Beta (reported)
1.79
5Y monthly, from filing
Short interest
Shares short
2.84M
Prior 3.41M
Change vs prior
-16.7%
Shorts covering
% of float
16.57%
Elevated
% of shares out
16.55%
Against total outstanding
Days to cover
6.7
Crowded exit
Float
14.12M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 25, 26 | Raymond James | INITIATED | — | Strong Buy |
| May 4, 26 | TD Cowen | INITIATED | — | Buy |
| Mar 20, 25 | Noble Capital Markets | MAINTAINED | Outperform | Outperform |
| Jul 22, 24 | Alliance Global Partners | MAINTAINED | Buy | Buy |
| Feb 28, 24 | Dawson James | INITIATED | — | Buy |
| Aug 1, 23 | Alliance Global Partners | MAINTAINED | Buy | Buy |
| Jun 2, 23 | Alliance Global Partners | MAINTAINED | Buy | Buy |
| Aug 31, 21 | Alliance Global Partners | MAINTAINED | Buy | Buy |
| Aug 11, 21 | Alliance Global Partners | MAINTAINED | Buy | Buy |
| Feb 25, 21 | Alliance Global Partners | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay dateNov 1, 2019
Last split1:100
Split dateFeb 5, 2025
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-10-02
Corporate Changes & Voting Matters
8-K · 2026-09-22
Corporate Changes & Voting Matters
8-K · 2026-09-08
Corporate Changes & Voting Matters
8-K · 2026-08-18
Periodic Financial Reports
10-Q · 2026-08-10
Corporate Changes & Voting Matters
8-K · 2026-08-03
Corporate Changes & Voting Matters
8-K · 2026-07-21
Corporate Changes & Voting Matters
8-K · 2026-07-13
Headlines
Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA®
GlobeNewswire · 15d ago
Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears
MarketBeat · 25d ago
Tonix Pharmaceuticals Promotes Thomas Englese, MBA, to Chief Commercial Officer
GlobeNewswire · 29d ago
TNXP: $11.0 Million in Tonmya® Net Revenue in 2Q26
Zacks Small Cap Research · 35d ago
Tonix Pharmaceuticals to Participate in Cantor’s 2026 Global Healthcare Conference
GlobeNewswire · 35d ago
Tonix Pharmaceuticals Highlights TONMYA Sales Surge, Lyme and Depression Pipeline
MarketBeat · 50d ago
Tonix Pharmaceuticals (TNXP) Q2 2026 Earnings Call Transcript
Motley Fool · 51d ago
Tonix Pharmaceuticals Holding Corp (TNXP) (Q2 2026) Earnings Call Highlights: TONMYA Surges ...
GuruFocus.com · 57d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.